Search research articles
Contact Us
Filters
Showing results (21-30 of 50) with videos related to
Page
of 5
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 1, 2026
Design, expression, purification, and application of novel recombinant miR-491 molecules to define the biogenesis and function of miR-491-3p versus -5p in posttranscriptional regulation of UDP-glucuronosyltransferase 1A1
Yimei Wang, Mei-Juan Tu, Neelu Batra, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 15, 2015
MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy
Ai-Ming Yu, Ye Tian, Mei-Juan Tu, et al.
Clinical Genitourinary Cancer
|
January 5, 2023
ATR Inhibition in Advanced Urothelial Carcinoma
Ryan C Leibrandt, Mei-Juan Tu, Ai-Ming Yu, et al.
Oncotarget
|
June 21, 2016
MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis
Mei-Juan Tu, Yu-Zhuo Pan, Jing-Xin Qiu, et al.
Acta Pharmaceutica Sinica. B
|
January 13, 2022
Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis <i>in vivo</i>
Linglong Deng, Hannah Petrek, Mei-Juan Tu, et al.
Acta Pharmaceutica Sinica. B
|
September 1, 2023
Erratum: Author correction to 'Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis <i>in vivo</i>' [Acta Pharmaceutica Sinica B 11 (2021) 3950-3965]
Linglong Deng, Hannah Petrek, Mei-Juan Tu, et al.
Acta Pharmaceutica Sinica. B
|
June 14, 2019
Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition <i>via</i> the regulation of target ADME gene expression
Xin Li, Ye Tian, Mei-Juan Tu, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 13, 2021
A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine <i>In Vivo</i> Synergism
Young Hee Choi, Chao Zhang, Zhenzhen Liu, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
June 10, 2019
A reliable LC-MS/MS method for the quantification of natural amino acids in mouse plasma: Method validation and application to a study on amino acid dynamics during hepatocellular carcinoma progression
Zhenzhen Liu, Mei-Juan Tu, Chao Zhang, et al.
Scientific Reports
|
May 25, 2016
Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest
Yong Zhao, Mei-Juan Tu, Wei-Peng Wang, et al.
Page
of 5
Search research articles
Search
Showing results (21-30 of 50) with videos related to
Sort By:
Page
of 5
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
May 1, 2026
Design, expression, purification, and application of novel recombinant miR-491 molecules to define the biogenesis and function of miR-491-3p versus -5p in posttranscriptional regulation of UDP-glucuronosyltransferase 1A1
Yimei Wang, Mei-Juan Tu, Neelu Batra, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
November 15, 2015
MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective Therapy
Ai-Ming Yu, Ye Tian, Mei-Juan Tu, et al.
Clinical Genitourinary Cancer
|
January 5, 2023
ATR Inhibition in Advanced Urothelial Carcinoma
Ryan C Leibrandt, Mei-Juan Tu, Ai-Ming Yu, et al.
Oncotarget
|
June 21, 2016
MicroRNA-1291 targets the FOXA2-AGR2 pathway to suppress pancreatic cancer cell proliferation and tumorigenesis
Mei-Juan Tu, Yu-Zhuo Pan, Jing-Xin Qiu, et al.
Acta Pharmaceutica Sinica. B
|
January 13, 2022
Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis <i>in vivo</i>
Linglong Deng, Hannah Petrek, Mei-Juan Tu, et al.
Acta Pharmaceutica Sinica. B
|
September 1, 2023
Erratum: Author correction to 'Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis <i>in vivo</i>' [Acta Pharmaceutica Sinica B 11 (2021) 3950-3965]
Linglong Deng, Hannah Petrek, Mei-Juan Tu, et al.
Acta Pharmaceutica Sinica. B
|
June 14, 2019
Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition <i>via</i> the regulation of target ADME gene expression
Xin Li, Ye Tian, Mei-Juan Tu, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
March 13, 2021
A Novel Integrated Pharmacokinetic-Pharmacodynamic Model to Evaluate Combination Therapy and Determine <i>In Vivo</i> Synergism
Young Hee Choi, Chao Zhang, Zhenzhen Liu, et al.
Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
|
June 10, 2019
A reliable LC-MS/MS method for the quantification of natural amino acids in mouse plasma: Method validation and application to a study on amino acid dynamics during hepatocellular carcinoma progression
Zhenzhen Liu, Mei-Juan Tu, Chao Zhang, et al.
Scientific Reports
|
May 25, 2016
Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest
Yong Zhao, Mei-Juan Tu, Wei-Peng Wang, et al.
Page
of 5